| abstract |
The disclosure describes humanized anti IL1RAP antibodies (Interleukin "1" receptor accessory protein, IL1R3). Several combinations of different CDRs are claimed. The antibodies can be used in cancer therapy. Examples are provided for 17 humanized antibodies (see Figures 2-4), with the following internal names : MAB-16-0015, MAB-16-0019, MAB-16-0021, MAB-16-0004, MAB-16-0009, MAB-16-0027, MAB-16-0030, MAB-16-0040, MAB-16-0043, MAB-16-0046, MAB-16-0049, MAB-16-0028, MAB-16-0031, MAB-16-0041, MAB-16-0036, MAB-16-0045, MAB-16-0048. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. |